va semaglutide criteria for use Nutritional priorities to support GLP-1 therapy obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society semaglutide va criteria for use
Description
Some patients may experience greater weight loss, lesser weight loss, or no significant weight loss
GLP-1 helps regulate blood sugar by stimulating insulin release, slowing digestion and signaling fullness to the brain
Some people may prefer to stick to the lower 1.7 mg per week or 2.4 mg dose as their maintenance dose
A multidisciplinary approach is essential as these drugs become more common
Given the potential adverse consequences of sarcopenic obesity there is a need to educate healthcare professionals about the risks and to incorporate lifestyle interventions to prevent gains in fat and optimise muscle mass following GLP-1 RA cessation
, Fischer, H
